← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
DAAQ
Digital Asset Acquisition Corp.
Valuation N/A
Financial Services
Price$10.44
Model IV—
P/IV—
Limited data — see page
DARE
Dare Bioscience, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$0.71
Model IV—
P/IV—
Market implies +7.4%/yr vs model +15.0% · below model
DAVA
Endava plc
Valuation N/A
Technology Risk 61 · High
Price$3.00
Model IV—
P/IV—
Limited data — see page
DB
DEUTSCHE BANK AKTIENGESELLSCHAFT
Valuation N/A
Financial Services Risk 54 · Elevated
Price$40.48
Model IV—
P/IV—
Limited data — see page
DBCA
D. Boral Acquisition I Corp.
Valuation N/A
Financial Services
Price$10.02
Model IV—
P/IV—
Limited data — see page
DBD
DIEBOLD NIXDORF, Inc
Valuation N/A
Technology Risk 46 · Elevated
Price$65.62
Model IV—
P/IV—
Market implies +47.7%/yr vs model +7.2% · above model
DBGI
Digital Brands Group, Inc.
Valuation N/A
Consumer Cyclical Risk 42 · Elevated
Price$6.00
Model IV—
P/IV—
Market implies +45.7%/yr vs model +2.0% · above model
DBL
DoubleLine Opportunistic Credit Fund
Valuation N/A
Unknown
Price$14.05
Model IV—
P/IV—
Limited data — see page
DBVT
DBV Technologies S.A.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$11.85
Model IV—
P/IV—
Market implies +93.1%/yr vs model +2.0% · above model
DC
Dakota Gold Corp.
Valuation N/A
Basic Materials Risk 37 · Moderate
Price$5.81
Model IV—
P/IV—
Market implies +64.0%/yr vs model +5.0% · above model
DCBO
Docebo Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$24.25
Model IV—
P/IV—
Limited data — see page
DCOY
Decoy Therapeutics Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$2.67
Model IV—
P/IV—
Limited data — see page
DCX
Digital Currency X Technology Inc.
Valuation N/A
Consumer Cyclical Risk 39 · Moderate
Price$0.54
Model IV—
P/IV—
Market implies +18.0%/yr vs model +8.0% · above model
DDC
DDC Enterprise Ltd
Valuation N/A
Consumer Defensive
Price$0.25
Model IV—
P/IV—
Limited data — see page
DDD
3D SYSTEMS CORP
Valuation N/A
Technology Risk 32 · Moderate
Price$3.32
Model IV—
P/IV—
Market implies +34.2%/yr vs model +2.0% · above model
DDL
Dingdong (Cayman) Ltd
Valuation N/A
Consumer Cyclical
Price$2.20
Model IV—
P/IV—
Limited data — see page
DDOG
Datadog, Inc.
Valuation N/A
Technology Risk 43 · Elevated
Price$230.05
Model IV—
P/IV—
Market implies +50.9%/yr vs model +25.0% · above model
DDS
DILLARD'S, INC.
Valuation N/A
Consumer Cyclical Risk 42 · Elevated
Price$650.57
Model IV—
P/IV—
Limited data — see page
DEFT
Defi Technologies, Inc.
Valuation N/A
Financial Services Risk 29 · Moderate
Price$0.58
Model IV—
P/IV—
Limited data — see page
DETX
LIBERTY DEFENSE HOLDINGS, LTD.
Valuation N/A
Industrials
Price$2.34
Model IV—
P/IV—
Limited data — see page
DFNS
T3 Defense Inc.
Valuation N/A
Industrials Risk 30 · Moderate
Price$9.59
Model IV—
P/IV—
Market implies +49.9%/yr vs model +15.0% · above model
DFP
Flaherty & Crumrine Dynamic Preferred & Income Fund Inc
Valuation N/A
Unknown
Price$19.74
Model IV—
P/IV—
Limited data — see page
DFSC
DEFSEC Technologies Inc.
Valuation N/A
Technology Risk 35 · Moderate
Price$1.43
Model IV—
P/IV—
Limited data — see page
DFTX
Definium Therapeutics, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$38.89
Model IV—
P/IV—
Limited data — see page
DGICA
DONEGAL GROUP INC
Valuation N/A
Financial Services
Price$19.36
Model IV—
P/IV—
Limited data — see page
DGICB
DONEGAL GROUP INC
Valuation N/A
Financial Services
Price$24.99
Model IV—
P/IV—
Limited data — see page
DGNX
Diginex Ltd
Valuation N/A
Technology Risk 40 · Elevated
Price$1.37
Model IV—
P/IV—
Limited data — see page
DGP
DEUTSCHE BANK AKTIENGESELLSCHAFT
Valuation N/A
Financial Services Risk 52 · Elevated
Price$156.78
Model IV—
P/IV—
Limited data — see page
DGXX
Digi Power X Inc.
Valuation N/A
Financial Services Risk 29 · Moderate
Price$3.81
Model IV—
P/IV—
Market implies +58.3%/yr vs model +15.0% · above model
DGZ
DEUTSCHE BANK AKTIENGESELLSCHAFT
Valuation N/A
Financial Services Risk 32 · Moderate
Price$5.16
Model IV—
P/IV—
Limited data — see page
DHC
DIVERSIFIED HEALTHCARE TRUST
Valuation N/A
Financial Services Risk 58 · Elevated
Price$7.50
Model IV—
P/IV—
Limited data — see page
DHCNI
DIVERSIFIED HEALTHCARE TRUST
Valuation N/A
Financial Services Risk 30 · Moderate
Price$17.89
Model IV—
P/IV—
Limited data — see page
DHCNL
DIVERSIFIED HEALTHCARE TRUST
Valuation N/A
Financial Services Risk 58 · Elevated
Price$18.72
Model IV—
P/IV—
Limited data — see page
DHF
BNY MELLON HIGH YIELD STRATEGIES FUND
Valuation N/A
Unknown
Price$2.27
Model IV—
P/IV—
Limited data — see page
DHT
DHT Holdings, Inc.
Valuation N/A
Industrials Risk 39 · Moderate
Price$22.15
Model IV—
P/IV—
Limited data — see page
DHY
CREDIT SUISSE HIGH YIELD CREDIT FUND
Valuation N/A
Unknown
Price$1.68
Model IV—
P/IV—
Limited data — see page
DIBS
1stdibs.com, Inc.
Valuation N/A
Consumer Cyclical Risk 31 · Moderate
Price$4.33
Model IV—
P/IV—
Market implies +39.0%/yr vs model +2.0% · above model
DIOD
DIODES INC /DEL/
Valuation N/A
Technology Risk 47 · Elevated
Price$95.01
Model IV—
P/IV—
Market implies +26.7%/yr vs model +3.0% · above model
DJCO
DAILY JOURNAL CORP
Valuation N/A
Communication Services Risk 47 · Elevated
Price$677.05
Model IV—
P/IV—
Market implies +50.9%/yr vs model +8.0% · above model
DJT
Trump Media & Technology Group Corp.
Valuation N/A
Technology Risk 35 · Moderate
Price$8.66
Model IV—
P/IV—
Market implies +124.6%/yr vs model +15.0% · above model
DLO
dLocal Ltd
Valuation N/A
Technology Risk 26 · Moderate
Price$14.86
Model IV—
P/IV—
Limited data — see page
DLXY
Delixy Holdings Ltd
Valuation N/A
Consumer Defensive Risk 46 · Elevated
Price$0.42
Model IV—
P/IV—
Market implies -50.0%/yr vs model +2.0% · below model
DLY
DoubleLine Yield Opportunities Fund
Valuation N/A
Unknown
Price$13.73
Model IV—
P/IV—
Limited data — see page
DMA
Destra Multi-Alternative Fund
Valuation N/A
Unknown
Price$7.66
Model IV—
P/IV—
Limited data — see page
DMAA
Drugs Made In America Acquisition Corp.
Valuation N/A
Financial Services Risk 29 · Moderate
Price$10.80
Model IV—
P/IV—
Limited data — see page
DMAAR
Drugs Made In America Acquisition Corp.
Valuation N/A
Financial Services Risk 43 · Elevated
Price$0.13
Model IV—
P/IV—
Limited data — see page
DMAC
DiaMedica Therapeutics Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$6.47
Model IV—
P/IV—
Limited data — see page
DMB
BNY Mellon Municipal Bond Infrastructure Fund, Inc.
Valuation N/A
Unknown
Price$9.89
Model IV—
P/IV—
Limited data — see page
DMII
Drugs Made In America Acquisition II Corp.
Valuation N/A
Financial Services Risk 27 · Moderate
Price$10.16
Model IV—
P/IV—
Limited data — see page
DMIIR
Drugs Made In America Acquisition II Corp.
Valuation N/A
Financial Services Risk 28 · Moderate
Price$0.08
Model IV—
P/IV—
Limited data — see page
DMO
Western Asset Mortgage Opportunity Fund Inc.
Valuation N/A
Unknown
Price$9.89
Model IV—
P/IV—
Limited data — see page
DMRA
Damora Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$28.39
Model IV—
P/IV—
Limited data — see page
DMRC
Digimarc Corp
Valuation N/A
Technology Risk 40 · Elevated
Price$5.04
Model IV—
P/IV—
Limited data — see page
DNA
Ginkgo Bioworks Holdings, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$6.75
Model IV—
P/IV—
Market implies +54.2%/yr vs model +2.0% · above model
DNLI
Denali Therapeutics Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$21.09
Model IV—
P/IV—
Market implies +33.7%/yr vs model +15.0% · above model
DNMX
Dynamix Corp III
Valuation N/A
Financial Services
Price$10.07
Model IV—
P/IV—
Limited data — see page
DNN
DENISON MINES CORP.
Valuation N/A
Basic Materials Risk 37 · Moderate
Price$3.02
Model IV—
P/IV—
Limited data — see page
DNP
DNP SELECT INCOME FUND INC
Valuation N/A
Unknown
Price$10.57
Model IV—
P/IV—
Limited data — see page
DNTH
Dianthus Therapeutics, Inc. /DE/
Valuation N/A
Healthcare Risk 41 · Elevated
Price$106.20
Model IV—
P/IV—
Market implies +116.9%/yr vs model +15.0% · above model
DOCN
DigitalOcean Holdings, Inc.
Valuation N/A
Technology Risk 50 · Elevated
Price$122.95
Model IV—
P/IV—
Market implies +32.8%/yr vs model +20.4% · above model